Journal
TRANSFUSION
Volume 61, Issue 4, Pages 1181-1190Publisher
WILEY
DOI: 10.1111/trf.16268
Keywords
-
Categories
Funding
- FundacAo de Amparo a Pesquisa do Estado de SAo Paulo (FAPESP) [2017/24769-2, 2016/20045-7, 2020/06409-1]
- CoordenacAo de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [88887.131387/2016-00]
Ask authors/readers for more resources
This study suggests that SARS-CoV-2 IgG immunoassays (S/CO) can predict high anti-SARS-CoV-2 nAbs titers. Different criteria for identifying donors with >= 1:160 nAbs titers have been proposed in this study, all showing high efficacy.
Background The efficacy of convalescent plasma (CP), an alternative for the treatment of COVID-19, depends on high titers of neutralizing antibodies (nAbs), but assays for quantifying nAbs are not widely available. Our goal was to develop a strategy to predict high titers of nAbs based on the results of anti-SARS-CoV-2 immunoassays and the clinical characteristics of CP donors. Study Design and Methods A total of 214 CP donors were enrolled and tested for the presence of anti-SARS-CoV-2 antibodies (IgG) using two commercial immunoassays: EUROIMMUN (ELISA) and Abbott (Chemiluminescence). Quantification of nAbs was performed using the Cytopathic Effect-based Virus Neutralization test. Three criteria for identifying donors with nAbs >= 1:160 were tested: - C1: Curve ROC; - C2: Conditional decision tree considering only the IA results and - C3: Conditional decision tree including both the IA results and the clinical variables. Results The performance of the immunoassays was similar referring to both S/CO and predictive value for identifying nAbs titers >= 1:160. Regarding the studied criteria for identifying CP donors with high nAbs titers: (a) C1 showed 76.1% accuracy if S/CO = 4.65, (b) C2 presented 76.1% accuracy if S/CO >= 4.57 and (c) C3 had 71.6% accuracy if S/CO was >= 4.57 or if S/CO was between 2.68-4.57 and the last COVID-19-related symptoms were recent (within 19 days). Conclusion SARS-CoV-2 IgG immunoassays (S/CO) can be used to predict high anti-SARS-CoV-2 nAbs titers. This study has proposed different criteria for identifying donors with >= 1:160 nAbs titers, all with high efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available